Orgenesis Inc. (ORGS): Price and Financial Metrics
ORGS Price/Volume Stats
| Current price | $1.19 | 52-week high | $2.70 |
| Prev. close | $1.22 | 52-week low | $0.98 |
| Day low | $1.19 | Volume | 7,800 |
| Day high | $1.24 | Avg. volume | 59,729 |
| 50-day MA | $1.16 | Dividend yield | N/A |
| 200-day MA | $1.65 | Market Cap | 33.72M |
ORGS Stock Price Chart Interactive Chart >
ORGS Stock Summary
- ORGENESIS INC's market capitalization of $34,006,201 is ahead of only 11.63% of US-listed equities.
- Over the past twelve months, ORGS has reported earnings growth of -181.08%, putting it ahead of merely 8.75% of US stocks in our set.
- ORGENESIS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -73.2%, greater than the shareholder yield of only 7.76% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to ORGENESIS INC are SIDU, ESCA, SCSC, TKR, and SNAX.
- Visit ORGS's SEC page to see the company's official filings. To visit the company's web site, go to www.orgenesis.com.
ORGS Valuation Summary
- In comparison to the median Healthcare stock, ORGS's price/sales ratio is 80.39% lower, now standing at 1.
- Over the past 136 months, ORGS's EV/EBIT ratio has gone up 977.5.
Below are key valuation metrics over time for ORGS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ORGS | 2023-05-23 | 1.0 | 1.3 | -2.3 | -4.4 |
| ORGS | 2023-05-22 | 0.9 | 1.2 | -2.1 | -4.1 |
| ORGS | 2023-05-19 | 0.9 | 1.2 | -2.1 | -4.1 |
| ORGS | 2023-05-18 | 0.9 | 1.1 | -2.1 | -4.1 |
| ORGS | 2023-05-17 | 0.9 | 1.2 | -2.2 | -4.2 |
| ORGS | 2023-05-16 | 0.9 | 1.1 | -2.0 | -4.0 |
ORGS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ORGS has a Quality Grade of F, ranking ahead of 4.67% of graded US stocks.
- ORGS's asset turnover comes in at 0.277 -- ranking 161st of 677 Pharmaceutical Products stocks.
- ACRX, ASMB, and JNJ are the stocks whose asset turnover ratios are most correlated with ORGS.
The table below shows ORGS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.277 | 0.850 | 4.262 |
| 2021-03-31 | 0.156 | 1.388 | 7.853 |
| 2020-12-31 | 0.070 | 1.000 | -0.286 |
| 2020-09-30 | 0.128 | 0.792 | -3.802 |
| 2020-06-30 | 0.209 | 0.571 | -3.077 |
| 2020-03-31 | 0.290 | 0.495 | -3.168 |
ORGS Price Target
For more insight on analysts targets of ORGS, see our ORGS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Orgenesis Inc. (ORGS) Company Bio
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company was founded in 2008 and is based in Germantown, Maryland.
Latest ORGS News From Around the Web
Below are the latest news stories about ORGENESIS INC that investors may wish to consider to help them evaluate ORGS as an investment opportunity.
Orgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master’s ProgramProgram prepares scientists to meet the accelerating demand for cell and gene therapy expertise across an industry already delivering cures for dangerous diseasesGERMANTOWN, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced the first graduating class from a unique Master of Science degree program in Cell and Gene Therapies, sponsored b |
Orgenesis to Participate in Benchmark’s 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced that Vered Caplan, CEO of Orgenesis, will be participating in the Benchmark Company’s 3rd Annual Healthcare House Call Virtual 1x1 Conference, which will be held on Tuesday, May 23, 2023. The conference offers its clients one-on-one and small-group virtua |
Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus VectorsGERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through its US-based point-of-care (POCare) services subsidiary, Morgenesis LLC (“Morgenesis”), has signed a collaboration agreement with SCTbio, a full-service contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors. The goal of the collabor |
Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare StrategyGERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023. Vered Caplan, CEO of Orgenesis, said, “We achieved revenue of approximately $7.0 million for the first quarter of 2023, which reflects the continued progress of our POCare strategy. We are currently focused on the i |
Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service SubsidiaryGERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and Metalmark Capital Partners (“Metalmark”), a leading private equity firm with extensive expertise in the healthcare sector, today announced that Metalmark has agreed to make an additional growth investment of $5 million into Orgenesis’ US-based point-of-care (POCare) |
ORGS Price Returns
| 1-mo | 11.21% |
| 3-mo | -14.39% |
| 6-mo | -40.50% |
| 1-year | -53.70% |
| 3-year | -83.63% |
| 5-year | -86.29% |
| YTD | -38.97% |
| 2022 | -32.29% |
| 2021 | -36.00% |
| 2020 | -3.43% |
| 2019 | -0.43% |
| 2018 | -18.68% |
Loading social stream, please wait...